Baseline characteristics of LA GVHD patients from the Chronic GVHD Consortium (cohort 1)
| Characteristic . | Recurrent (n = 48) . | De novo (n = 35) . | P value . |
|---|---|---|---|
| Age (y) at transplant; median (range) | 49.7 (19.3-71.4) | 59.5 (22.2-73.0) | .01 |
| Gender | .87 | ||
| Female | 17 (35%) | 13 (37%) | |
| Male | 31 (65%) | 22 (63%) | |
| Diagnosis | .80 | ||
| Chronic leukemia | 2 (4%) | 2 (6%) | |
| Acute leukemia | 28 (58%) | 18 (51%) | |
| MDS | 8 (17%) | 4 (11%) | |
| HD/NHL | 3 (6%) | 4 (11%) | |
| Other | 7 (15%) | 7 (20%) | |
| Disease risk | .87 | ||
| Early | 26 (54%) | 17 (49%) | |
| Intermediate | 18 (38%) | 15 (43%) | |
| Advanced | 4 (8%) | 3 (9%) | |
| Donor | .24 | ||
| Matched related | 10 (21%) | 13 (37%) | |
| Matched unrelated | 22 (46%) | 14 (40%) | |
| Mismatched | 15 (33%) | 8 (23%) | |
| Conditioning | .01 | ||
| Myeloablative | 27 (56%) | 10 (29%) | |
| Reduced intensity | 21 (44%) | 25 (71%) | |
| Stem cell source | .57 | ||
| BM | 2 (4%) | 2 (6%) | |
| PBSC | 40 (83%) | 31 (89%) | |
| Umbilical cord blood | 6 (13%) | 2 (6%) | |
| GVHD prophylaxis | |||
| Tac + Mtx | 7 (25%) | 29 (53%) | .02 |
| Tac + MMF | 7 (25%) | 11 (20%) | .60 |
| Csp + Mtx | 1 (4%) | 1 (2%) | .62 |
| Csp and MMF | 10 (36%) | 8 (15%) | .03 |
| Use of ATG or alemtuzumab | 1 (4%) | 3 (5%) | .70 |
| CMV serostatus | .42 | ||
| D− and R− | 16 (34%) | 9 (26%) | |
| D+ or R+ | 31 (66%) | 26 (74%) |
| Characteristic . | Recurrent (n = 48) . | De novo (n = 35) . | P value . |
|---|---|---|---|
| Age (y) at transplant; median (range) | 49.7 (19.3-71.4) | 59.5 (22.2-73.0) | .01 |
| Gender | .87 | ||
| Female | 17 (35%) | 13 (37%) | |
| Male | 31 (65%) | 22 (63%) | |
| Diagnosis | .80 | ||
| Chronic leukemia | 2 (4%) | 2 (6%) | |
| Acute leukemia | 28 (58%) | 18 (51%) | |
| MDS | 8 (17%) | 4 (11%) | |
| HD/NHL | 3 (6%) | 4 (11%) | |
| Other | 7 (15%) | 7 (20%) | |
| Disease risk | .87 | ||
| Early | 26 (54%) | 17 (49%) | |
| Intermediate | 18 (38%) | 15 (43%) | |
| Advanced | 4 (8%) | 3 (9%) | |
| Donor | .24 | ||
| Matched related | 10 (21%) | 13 (37%) | |
| Matched unrelated | 22 (46%) | 14 (40%) | |
| Mismatched | 15 (33%) | 8 (23%) | |
| Conditioning | .01 | ||
| Myeloablative | 27 (56%) | 10 (29%) | |
| Reduced intensity | 21 (44%) | 25 (71%) | |
| Stem cell source | .57 | ||
| BM | 2 (4%) | 2 (6%) | |
| PBSC | 40 (83%) | 31 (89%) | |
| Umbilical cord blood | 6 (13%) | 2 (6%) | |
| GVHD prophylaxis | |||
| Tac + Mtx | 7 (25%) | 29 (53%) | .02 |
| Tac + MMF | 7 (25%) | 11 (20%) | .60 |
| Csp + Mtx | 1 (4%) | 1 (2%) | .62 |
| Csp and MMF | 10 (36%) | 8 (15%) | .03 |
| Use of ATG or alemtuzumab | 1 (4%) | 3 (5%) | .70 |
| CMV serostatus | .42 | ||
| D− and R− | 16 (34%) | 9 (26%) | |
| D+ or R+ | 31 (66%) | 26 (74%) |
ATG, antithymocyte globulin; BM, bone marrow; CMV, cytomegalovirus; Csp, cyclosporine; D−/R−, donor negative/recipient negative; HD/NHL, Hodgkin’s disease/non-Hodgkin’s lymphoma; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; Mtx, methotrexate; PBSC, peripheral blood stem cells; Tac, tacrolimus.